Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer's disease
Sha Sha1
Lina Ren1
Xiaona Xing2
Wanshu Guo3
Yan Wang1
Ying Li1
Yunpeng Cao4
Le Qu5
1.Department of Geriatrics,the First Affiliated Hospital of China Medical University,Shenyang,Liaoning Province,China2.Department of Neurology,Shenzhen Luohu People's Hospital,The Third Affiliated Hospital of Shenzhen University,Shenzhen,Guangdong Province,China3.Department of Neurology,People's Hospital of Liaoning Province,Shenyang,Liaoning Province,China4.Department of Neurology,the First Affiliated Hospital of China Medical University,Shenyang,Liaoning Province,China5.Department of Dermatology,the First Affiliated Hospital of China Medical University,Shenyang,Liaoning Province,China
摘要：Alzheimer's disease,a devastating neurodegenerative disorder,is characterized by progressive cognitive decline,primarily due to amyloid-beta protein deposition and tau protein phosphorylation.Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer's disease.Conventional drugs,such as donepezil,can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline.Currently,active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer's disease and other transgenic animal models,attracting considerable attention.However,the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab.This review first discusses the advancements in the pathogenesis of Alzheimer's disease and active and passive immunotherapies targeting amyloid-beta and tau proteins.Furthermore,it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects.Although some antibodies have shown promise in patients with mild Alzheimer's disease,substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer's disease.
机标关键词：immunotherapyalzheimeradvancesamyloid-betadiseaserecenttargetingtauopathies
论文发表日期：2026-02-28
在线出版日期：2025-12-09（本平台首次上网日期，不代表文献的发表时间）
页数：11( 577-587 )
英文信息